COMPANY PROFILE // THE 014 REPORT
Yarrow Bioscience, Inc.
YARW (Nasdaq) · Formerly: VYNE Therapeutics Inc.; Menlo Therapeutics Inc.; Menlo Therapeutics, Inc.; Tigercat Pharma, Inc.
Assembled from 2 government sources in 3.3 s
FLAGS · DISCLOSURE · SUMMARY
Missing or hidden
- Amber8-K Item 3.01 filed: notice of delisting, of a failed continued-listing rule, or of a transfer of listing on 2026-03-11 and 1 more time (last 24 months).
- InfoRegistered business address (470 JAMES STREET, SUITE 007, NEW HAVEN) is shared with 19 other entities in our records (SEC registrants and IRS-registered organizations).
✓ SEC filings✓ State registrationpossible match✗ LEI✗ SAM registration✗ IRS return✗ Website✗ Lobbying registration
No LEI, no SAM registration, no IRS return, no website, no lobbying registration on record; address shared with 19 entities.
Yarrow Bioscience, Inc. is an SEC-registered operating company in pharmaceutical preparations, incorporated in DE, based in New Haven, CT; listed as YARW (Nasdaq).[source] It reported revenue of $570,000 for the fiscal year ended 2025-12-31.[source] It has filed 101 documents with the SEC in the last 12 months; the latest is a SCHEDULE 13G/A, filed 2026-11-17.[source] Seraphix flags 1 item from these records: 8-K Item 3.01 filed.[source]
- red0
- amber1
- info1
- CLEAR26
- POSSIBLE MATCH0
- MATCH0
RECORD · WEB
Ask about this entity
Answers come from this 014 first; every line is marked RECORD (our record, linked) or WEB (a web page, credited and linked).
PEOPLE · COUNSEL · LINKS
Leadership, advisers and links
Officers and directors (Forms 3, 4, 5)
- Domzalski David · PRESIDENT AND CEO (Director,Officer) · latest Form 4 2026-01-05 · filing · LinkedIn search
- Harsch Mutya · CHIEF LEGAL OFFICER AND GC (Officer) · latest Form 4 2026-01-05 · filing · LinkedIn search
- Stuart Iain · CHIEF SCIENTIFIC OFFICER (Officer) · latest Form 4 2026-01-05 · filing · LinkedIn search
- Zeronda Tyler · CHIEF FINANCIAL OFFICER (Officer) · latest Form 4 2026-01-05 · filing · LinkedIn search
- BARBARI SHARON · Director · latest Form 4 2025-12-15 · filing · LinkedIn search
- Basta Steven L · Director · latest Form 4 2025-12-15 · filing · LinkedIn search
- LEPORE PATRICK G · Director · latest Form 4 2025-12-15 · filing · LinkedIn search
- Little Elisabeth Sandoval · Director · latest Form 4 2025-12-15 · filing · LinkedIn search
As reported to the SEC by the insiders themselves; SEC insider transactions data sets (Forms 3, 4, 5): 2026q1, 2025q4, 2025q3, 2025q2.
Legal counsel, as publicly named
- Mark Ballantyne Mark Ballantyne Cooley LLP · Exhibit 5.1 legal opinion, S-8 filed 2024-12-19
EVERY LIST AND SOURCE · DATED
Checked and clear
26 lists and sources checked: 26 CLEAR, 0 POSSIBLE MATCH, 0 MATCH. Screening lists are checked when this 014 is built; the enforcement and registry sources at the last company-engine build. Each date is the date of that check.
EVERY IDENTIFIER · LINKED
ID crosswalk
| Identifier | Value | Record |
|---|---|---|
| SEC CIK | 0001566044 | source |
| EIN | 45-3757789 | source |
| Connecticut business ID | 3366353 | record |
| Business address (SEC) | 470 JAMES STREET, SUITE 007, NEW HAVEN, CT, 06513 | source |
Does not exist in the records we hold: LEI, UEI, NY DOS ID, FDIC certificate.
EACH FEEDS WATCH
Dates coming up
- 2027-03-31 · in 131 days · Next 10-K due (period ended 2026-12-31; Non-accelerated filer<br>Smaller reporting company) (computed from the fiscal year end and filer status)
- 2027-05-15 · in 176 days · Next 10-Q due (period ended 2027-03-31; Non-accelerated filer<br>Smaller reporting company) (computed from the fiscal year end and filer status)
PEERS BY SIC CODE
Industry context
SIC 2834 (pharmaceutical preparations): 568 companies in our records share this code.
federal dollars
lobbying filings
SEC filings in 12 months
flags
Peers, each with its 014
- PFIZER INC · 124 SEC filings in 12 months · $25.74B federal (possible match)
- Merck & Co., Inc. · 150 SEC filings in 12 months · $13.51B federal (possible match)
- ABBOTT LABORATORIES · 118 SEC filings in 12 months · 1 flag · $2.64B federal (possible match)
- ASTRAZENECA PLC · 140 SEC filings in 12 months · $602.8M federal (possible match)
- TEVA PHARMACEUTICAL INDUSTRIES LTD · 168 SEC filings in 12 months · $77.6M federal (possible match)
- NOVARTIS AG · 34 SEC filings in 12 months · $41.9M federal (possible match)
- Spero Therapeutics, Inc. · 41 SEC filings in 12 months · 4 flags · $39.5M federal (possible match)
- Grifols SA · 18 SEC filings in 12 months · $22.5M federal (possible match)
- SCYNEXIS INC · 54 SEC filings in 12 months · 3 flags · $18.5M federal (possible match)
- Ensysce Biosciences, Inc. · 45 SEC filings in 12 months · 3 flags · $15.1M federal (possible match)
- UNITED THERAPEUTICS Corp · 454 SEC filings in 12 months · 2 flags · $6.8M federal (possible match)
- Zoetis Inc. · 144 SEC filings in 12 months · 1 flag · $6.7M federal (possible match)
ADDRESS · ZIP CODE
Location context
At the same address (20)
- Veradermics, Inc · SEC registrant
- ARCHITECTURE RESOURCE CENTER INC · IRS-registered organization
- AIA CONNECTICUT · IRS-registered organization
- ADVANCECT INC · IRS-registered organization
- AMISTAD ACADEMY INC · IRS-registered organization
- ACHIEVEMENT FIRST BROOKLYN CHARTER SCHOOLS · IRS-registered organization
- ELM CITY COLLEGE PREPARATORY INC · IRS-registered organization
- ECONOMIC DEVELOPMENT CORPORATION OF NEW HAVEN · IRS-registered organization
- ACHIEVEMENT FIRST HARTFORD ACADEMY INC · IRS-registered organization
- QUANTUMCT INC · IRS-registered organization
- ACHIEVEMENT FIRST BRIDGEPORT ACADEMY INC · IRS-registered organization
- NATIONAL DIAPER BANK NETWORK · IRS-registered organization
SHARED PEOPLE · SHARED ADDRESS
Network neighbours
Shared directors and officers
- Phathom Pharmaceuticals, Inc. · Basta Steven L
- PROCEPT BioRobotics Corp · Little Elisabeth Sandoval
SEC registrants at the same address
EVERY SOURCE · NEWEST FIRST
One timeline
- 2026-11-13 filing S-8 · SEC EDGAR
- 2026-11-13 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-11-12 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-09-14 filing 8-K items 1.01,9.01 · SEC EDGAR
- 2026-09-11 filing 424B5 · SEC EDGAR
- 2026-09-11 filing 424B5 · SEC EDGAR
- 2026-09-10 filing 8-K items 8.01,9.01 · SEC EDGAR
- 2026-08-19 filing EFFECT · SEC EDGAR
- 2026-08-14 filing POS AM · SEC EDGAR
- 2026-08-13 filing 8-K/A items 2.02,7.01,9.01 · SEC EDGAR
- 2026-08-13 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-08-05 filing SCHEDULE 13D · SEC EDGAR
- 2026-07-30 filing 8-K items 8.01 · SEC EDGAR
- 2026-07-29 filing SCHEDULE 13D/A · SEC EDGAR
- 2026-07-28 officer change 8-K items 1.01,2.01,2.02,3.02,3.03,5.01,5.02,5.03,5.05,7.01,9.01 · SEC EDGAR
- 2026-07-24 name change Name changed from VYNE Therapeutics Inc. · SEC EDGAR
- 2026-07-21 filing 8-K items 7.01,8.01,9.01 · SEC EDGAR
- 2026-07-20 filing 8-K items 5.07 · SEC EDGAR
- 2026-07-14 filing 425 · SEC EDGAR
- 2026-07-14 filing 8-K items 7.01,9.01 · SEC EDGAR
- 2026-07-10 filing 425 · SEC EDGAR
- 2026-07-10 filing 8-K items 7.01,8.01,9.01 · SEC EDGAR
- 2026-06-16 filing ARS · SEC EDGAR
- 2026-06-15 filing EFFECT · SEC EDGAR
- 2026-06-15 filing 424B3 · SEC EDGAR
- 2026-06-03 filing S-4/A · SEC EDGAR
- 2026-05-21 filing 8-K items 7.01,9.01 · SEC EDGAR
- 2026-05-15 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-04-28 filing S-4/A · SEC EDGAR
- 2026-03-31 filing S-4 · SEC EDGAR
144 earlier entries
- 2026-03-11 filing 8-K items 3.01
- 2026-02-27 filing Annual report (10-K)
- 2026-01-30 filing DRS
- 2026-01-30 filing 425
- 2026-01-30 filing 8-K items 1.01,9.01
- 2025-12-17 filing 425
- 2025-12-17 officer change 8-K items 1.01,3.02,5.01,5.02,7.01,9.01
- 2025-12-15 insider First Form 3/4/5 on record for BARBARI SHARON (Director)
- 2025-12-15 insider First Form 3/4/5 on record for Basta Steven L (Director)
- 2025-12-15 insider First Form 3/4/5 on record for LEPORE PATRICK G (Director)
- 2025-12-15 insider First Form 3/4/5 on record for Little Elisabeth Sandoval (Director)
- 2025-12-12 filing 8-K items 5.07
- 2025-11-12 filing ARS
- 2025-11-12 filing Proxy statement
- 2025-11-06 filing Quarterly report (10-Q)
- 2025-11-06 filing 8-K items 2.02,9.01
- 2025-09-12 filing 8-K items 3.01
- 2025-08-14 filing Quarterly report (10-Q)
- 2025-08-14 officer change 8-K items 2.02,5.02,9.01
- 2025-07-30 filing 8-K items 2.02,8.01,9.01
- 2025-05-08 filing Quarterly report (10-Q)
- 2025-05-08 filing 8-K items 2.02,9.01
- 2025-04-02 insider First Form 3/4/5 on record for Domzalski David (PRESIDENT AND CEO)
- 2025-04-02 insider First Form 3/4/5 on record for Harsch Mutya (CHIEF LEGAL OFFICER AND GC)
- 2025-04-02 insider First Form 3/4/5 on record for Stuart Iain (CHIEF SCIENTIFIC OFFICER)
- 2025-04-02 insider First Form 3/4/5 on record for Zeronda Tyler (CHIEF FINANCIAL OFFICER)
- 2025-03-06 filing Annual report (10-K)
- 2025-03-06 filing 8-K items 2.02,9.01
- 2025-01-13 filing 8-K items 8.01,9.01
- 2024-12-23 filing 8-K items 8.01,9.01
- 2024-12-19 filing S-8
- 2024-12-12 officer change 8-K items 5.02,5.07,9.01
- 2024-11-12 filing ARS
- 2024-11-12 filing Proxy statement
- 2024-11-07 filing Quarterly report (10-Q)
- 2024-11-07 filing 8-K items 2.02,9.01
- 2024-09-12 filing 8-K items 8.01,9.01
- 2024-08-14 filing Quarterly report (10-Q)
- 2024-08-14 filing 8-K items 2.02,9.01
- 2024-05-09 filing Quarterly report (10-Q)
- 2024-05-09 filing 8-K items 2.02,9.01
- 2024-03-14 filing EFFECT
- 2024-03-12 filing CORRESP
- 2024-03-06 filing UPLOAD
- 2024-03-01 filing S-3
- 2024-03-01 filing S-8
- 2024-03-01 filing Annual report (10-K)
- 2024-02-29 filing 8-K items 2.02,9.01
- 2024-01-03 officer change 8-K items 5.02,7.01,9.01
- 2023-12-13 filing S-8
- 2023-12-13 officer change 8-K items 5.02,5.07,9.01
- 2023-11-22 filing EFFECT
- 2023-11-22 filing 424B3
- 2023-11-20 filing CORRESP
- 2023-11-17 filing UPLOAD
- 2023-11-16 filing D
- 2023-11-13 filing S-3
- 2023-11-13 filing ARS
- 2023-11-13 filing Proxy statement
- 2023-11-13 filing SC 13D
- 2023-11-13 filing Quarterly report (10-Q)
- 2023-11-13 filing 8-K items 2.02,9.01
- 2023-10-30 filing 8-K items 1.01,1.02,2.02,3.02,5.08,7.01,8.01,9.01
- 2023-08-14 filing Quarterly report (10-Q)
- 2023-08-14 filing 8-K items 2.02,9.01
- 2023-05-11 filing Quarterly report (10-Q)
- 2023-05-11 filing 8-K items 2.02
- 2023-05-01 filing 8-K items 1.01,7.01,9.01
- 2023-03-14 filing Annual report (10-K)
- 2023-03-09 filing 8-K items 2.02,9.01
- 2023-02-28 filing 8-K items 1.01,7.01,9.01
- 2023-02-10 filing 8-K items 3.03,5.03,9.01
- 2023-01-17 filing 8-K items 5.03,9.01
- 2023-01-12 filing 8-K items 2.02,5.07,7.01,8.01
- 2022-11-25 filing Proxy statement
- 2022-11-18 filing D
- 2022-11-14 filing PRE 14A
- 2022-11-14 filing Quarterly report (10-Q)
- 2022-11-10 filing 8-K items 2.02,7.01,9.01
- 2022-08-30 filing 8-K items 3.01,8.01
- 2022-08-12 filing Quarterly report (10-Q)
- 2022-08-12 filing 8-K items 2.02,9.01
- 2022-08-10 filing 8-K items 5.07,8.01,9.01
- 2022-07-28 filing DEFA14A
- 2022-07-27 filing 8-K items 7.01,9.01
- 2022-07-19 filing DEFA14A
- 2022-07-07 filing DEFA14A
- 2022-06-17 filing Proxy statement
- 2022-06-17 filing 8-K items 1.01,8.01,9.01
- 2022-06-07 filing PRE 14A
- 2022-05-17 filing 8-K items 7.01,9.01
- 2022-05-12 filing 424B5
- 2022-05-12 filing Quarterly report (10-Q)
- 2022-05-12 filing 8-K items 2.02,9.01
- 2022-04-07 filing 8-K items 4.01,8.01,9.01
- 2022-03-30 filing 8-K items 8.01,9.01
- 2022-03-17 filing S-8
- 2022-03-17 filing Annual report (10-K)
- 2022-03-17 filing 8-K items 2.02,9.01
- 2022-03-15 officer change 8-K items 1.01,5.02,9.01
- 2022-03-15 filing 424B5
- 2022-03-08 filing 8-K items 7.01
- 2022-03-07 filing 8-K items 8.01,9.01
- 2022-03-04 filing 8-K items 3.01
- 2022-01-19 filing 8-K items 8.01,9.01
- 2022-01-14 officer change 8-K/A items 5.02,9.01
- 2022-01-13 filing 8-K items 1.01,2.01,8.01,9.01
- 2022-01-05 filing 8-K items 7.01,9.01
- 2021-11-10 filing Quarterly report (10-Q)
- 2021-11-10 filing 8-K items 2.02,7.01,9.01
- 2021-11-04 filing 8-K items 8.01,9.01
- 2021-10-26 filing 8-K items 8.01,9.01
- 2021-10-19 filing 8-K items 8.01,9.01
- 2021-09-03 officer change 8-K items 5.02
- 2021-08-12 filing 8-K items 1.01,9.01
- 2021-08-12 filing 424B5
- 2021-08-12 filing 8-K items 8.01,9.01
- 2021-08-12 filing Quarterly report (10-Q)
- 2021-08-12 filing 8-K items 1.01,2.02,7.01,9.01
- 2021-08-09 filing 8-K items 8.01
- 2021-07-19 filing 8-K items 5.03,5.07,9.01
- 2021-07-02 filing 8-K items 8.01
- 2021-06-29 filing DEFA14A
- 2021-06-07 filing DEFA14A
- 2021-06-07 filing Proxy statement
- 2021-06-07 officer change 8-K items 5.02
- 2021-05-26 filing PRE 14A
- 2021-05-14 filing EFFECT
- 2021-05-11 filing CORRESP
- 2021-05-10 filing UPLOAD
- 2021-05-06 filing S-3
- 2021-05-06 filing Quarterly report (10-Q)
- 2021-05-06 filing 8-K items 2.02,9.01
- 2021-04-20 filing 10-K/A
- 2021-03-30 filing 8-K items 7.01,9.01
- 2021-03-04 filing S-8
- 2021-03-04 filing 8-K items 7.01,9.01
- 2021-03-04 filing Annual report (10-K)
- 2021-03-04 filing 8-K items 2.02,9.01
- 2021-03-01 filing 8-K items 7.01,9.01
- 2021-02-16 filing 8-K items 7.01
- 2020-09-02 name change Name changed from Menlo Therapeutics Inc.
- 2018-01-31 name change Name changed from Menlo Therapeutics, Inc.
- 2013-01-07 name change Name changed from Tigercat Pharma, Inc.
RENDERED FROM THIS PAGE
Relationship graph
Holders from 13F filings, subsidiaries from the GLEIF tree (by LEI), lobbying firms from LDA (possible match), agencies from USAspending, people from Forms 3/4/5, counsel from Exhibit 5.1, shared boards from Forms 3/4/5.
DATA MOTION // NEWEST FIRSTWhat changed
- 2026-11-13 (within 30 days) S-8 filed (FORM S-8)
- 2026-11-13 (within 30 days) 10-Q filed
- 2026-11-12 (within 30 days) 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-09-14 (older) 8-K filed: Item 1.01 material agreement; Item 9.01 exhibits
- 2026-09-11 (older) 424B5 filed
- 2026-09-11 (older) 424B5 filed
- 2026-09-10 (older) 8-K filed: Item 8.01 other event; Item 9.01 exhibits
- 2026-08-19 (older) EFFECT filed
Dot rule: red = within 7 days, amber = within 30 days, green = older. Measured against 2026-11-21; the colour is also written out in words.
PRICE · FILINGS · POSTS · NEWSMarket & news
- Price
- NASDAQ:YARW The chart widget (TradingView) shows the price and the previous session's close. Seraphix publishes no price of its own.
- Open in
Open in…
Price and chart
News
Analyst estimates and earnings
Institutional holders
Short interest
Official social
Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.
- Financials
- Filed figures: published SEC values, each linked to its filing.
- Official posts
- Links to posts from the company's and agencies' verified accounts: not connected yet.
- News
- Article links (headline, date, link): not connected yet.
EVERY RESOLVED IDENTIFIER1. Identity
2 possible matches held apart, matched by name only, not counted above; 1 record under a former name, shown apart.
| Identifier | Value | How it was resolved | Source |
|---|---|---|---|
| SEC CIK | 1566044 | id:sec-anchor: the SEC registrant record of this company | SEC EDGAR |
| Ticker / exchange | YARW / Nasdaq | SEC company record: ticker and exchange as listed on the SEC company record | SEC EDGAR |
| EIN | 453757789 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0001566044 | SEC EDGAR / IRS |
| CUSIP | 92941V407 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0001566044 | SEC EDGAR |
former name (shown apart, not merged) (1)
- former nameVyne Therapeutics Inc. · ClinicalTrials.gov
AS FILED · EACH WITH ITS DATE AND FILING2. Filed figures
Key figures (annual filing)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Revenue (fiscal year ended 2025-12-31) | $570,000 | 2025-12-31 | 10-K, XBRL RevenueFromContractWithCustomerExcludingAssessedTax | as filed | 2026-11-21 00:44 UTC | Report an error |
| Net income (loss) (fiscal year ended 2025-12-31) | -$26,483,000 | 2025-12-31 | 10-K, XBRL NetIncomeLoss | as filed | 2026-11-21 00:44 UTC | Report an error |
| Total assets (at 2025-12-31) | $30,160,000 | 2025-12-31 | 10-K, XBRL Assets | as filed | 2026-11-21 00:44 UTC | Report an error |
| Stockholders' equity (at 2025-12-31) | $27,765,000 | 2025-12-31 | 10-K, XBRL StockholdersEquity | as filed | 2026-11-21 00:44 UTC | Report an error |
| Cash and cash equivalents (at 2025-12-31) | $24,027,000 | 2025-12-31 | 10-K, XBRL CashAndCashEquivalentsAtCarryingValue | as filed | 2026-11-21 00:44 UTC | Report an error |
Company profile facts (SEC)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| SEC entity type | operating | 2026-11-17 | SEC EDGAR company profile | as filed | 2026-11-21 00:44 UTC | Report an error |
| SIC industry | 2834 Pharmaceutical Preparations | 2026-11-17 | SEC EDGAR company profile | as filed | 2026-11-21 00:44 UTC | Report an error |
| State of incorporation | DE | 2026-11-17 | SEC EDGAR company profile | as filed | 2026-11-21 00:44 UTC | Report an error |
| Fiscal year end (MMDD) | 1231 | 2026-11-17 | SEC EDGAR company profile | as filed | 2026-11-21 00:44 UTC | Report an error |
| Business address | 470 JAMES STREET, SUITE 007, NEW HAVEN, CT, 06513 | 2026-11-17 | SEC EDGAR company profile | as filed | 2026-11-21 00:44 UTC | Report an error |
| Exchanges | Nasdaq | 2026-11-17 | SEC EDGAR company profile | as filed | 2026-11-21 00:44 UTC | Report an error |
Other filed values
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Operating cash flow (fiscal year ended 2025-12-31) | -$33,124,000 | 2025-12-31 | 10-K, XBRL NetCashProvidedByUsedInOperatingActivities | as filed | 2026-11-21 00:44 UTC | Report an error |
| Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31) | $0 | 2025-12-31 | 10-K, XBRL PaymentsToAcquireProductiveAssets | as filed | 2026-11-21 00:44 UTC | Report an error |
| Long-term debt (at 2025-12-31) | $0 | 2025-12-31 | 10-K, XBRL LongTermDebt | as filed | 2026-11-21 00:44 UTC | Report an error |
| Operating lease liabilities (at 2024-12-31) | $99,000 | 2024-12-31 | 10-K, XBRL OperatingLeaseLiability | as filed | 2026-11-21 00:44 UTC | Report an error |
| Form D total offering amount (D filed 2023-11-16) | $88,151,508 | 2023-11-16 | D | as filed | 2026-11-21 00:44 UTC | Report an error |
| Form D total amount sold (D filed 2023-11-16) | $88,151,508 | 2023-11-16 | D | as filed | 2026-11-21 00:44 UTC | Report an error |
| Form D industry group | Biotechnology | 2023-11-16 | D | as filed | 2026-11-21 00:44 UTC | Report an error |
| Form D revenue range | Decline to Disclose | 2023-11-16 | D | as filed | 2026-11-21 00:44 UTC | Report an error |
| Form D date of first sale | 2023-11-01 | 2023-11-16 | D | as filed | 2026-11-21 00:44 UTC | Report an error |
Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-13 · accession 0001566044-26-000019
| Item | Value | Period | Form | Filed | Accession | Retrieved | Report |
|---|---|---|---|---|---|---|---|
| Net income (loss) | -$9,724,000 | 3 months ended 2026-09-30 | 10-Q | 2026-11-13 | 0001566044-26-000019 | 2026-11-21 00:44 UTC | Report an error |
| Cash and cash equivalents | $268,860,000 | at 2026-09-30 | 10-Q | 2026-11-13 | 0001566044-26-000019 | 2026-11-21 00:44 UTC | Report an error |
Values as filed in XBRL (SEC company facts); quarterly values are the filer's own 3-month figures, never derived.
No estimates: every value is as filed and links to the filing it came from.
Registration: the SEC filer status is under "Company profile facts (SEC)" above. SAM.gov registration status: not held yet.
NEWEST FIRST · EACH LINKS TO ITS FILING3. Registration and filing timeline
- 2026-11-13 Filing S-8 filed (FORM S-8)
- 2026-11-13 Filing 10-Q filed
- 2026-11-12 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-09-14 Filing 8-K filed: Item 1.01 material agreement; Item 9.01 exhibits
- 2026-09-11 Filing 424B5 filed
- 2026-09-11 Filing 424B5 filed
- 2026-09-10 Filing 8-K filed: Item 8.01 other event; Item 9.01 exhibits
- 2026-08-19 Filing EFFECT filed
- 2026-08-14 Filing POS AM filed
- 2026-08-13 Filing 8-K/A filed: Item 2.02 results of operations; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-08-13 Filing 10-Q filed
- 2026-07-30 Filing 8-K filed: Item 8.01 other event
- 2026-07-28 Filing 8-K filed: Item 1.01 material agreement; Item 2.01 acquisition or disposition; Item 2.02 results of operations; Item 3.02 unregistered equity sale; Item 3.03 rights of holders modified; Item 5.01 change in control; Item 5.02 officer or director change; Item 5.03 charter or bylaw amendment; Item 5.05; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-07-21 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 8.01 other event; Item 9.01 exhibits
- 2026-07-20 Filing 8-K filed: Item 5.07 shareholder vote
- 2026-07-14 Filing 425 filed
- 2026-07-14 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-07-10 Filing 425 filed
- 2026-07-10 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 8.01 other event; Item 9.01 exhibits
- 2026-06-16 Filing ARS filed
- 2026-06-15 Filing EFFECT filed
- 2026-06-15 Filing 424B3 filed
- 2026-06-03 Filing S-4/A filed
- 2026-05-21 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-05-15 Filing 10-Q filed
8-K item text, as filed (excerpts)
- 2026-11-12 8-K Item 2.02, Results of Operations and Financial Condition
On November 12, 2026, Yarrow Bioscience, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2026. The press release is being furnished as Exhibit 99.1 to this Current Report and is incorporated herein by reference. The information in Item 2.02 of this Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in… the 8-K · retrieved 2026-11-21 00:44 UTC - 2026-09-14 8-K Item 1.01
Entry into a Material Definitive Agreement. On September 10, 2026, Yarrow Bioscience, Inc. (the “Company”) entered into an underwriting agreement (“Underwriting Agreement”) with Jefferies LLC, TD Securities (USA) LLC and Guggenheim Securities, LLC, as the representatives of the underwriters named therein (the “Underwriters”), to issue and sell 5,769,231 shares of the Company’s common stock at a public offering price of $26.00 per share (the “Offering”). In addition, the Company has granted the Underwriters an option (the “Option”) for a period of 30 days to purchase up to an additional 865,384 shares of its common stock at the public offering price, less the underwriting discounts and… the 8-K · retrieved 2026-11-21 00:44 UTC - 2026-09-10 8-K Item 8.01
Other Events. Corporate Presentation On September 10, 2026, Yarrow Bioscience, Inc., a Delaware corporation (the “Company”), made available the Company’s investor presentation to be used in general corporate communications and investor communications. A copy of the corporate presentation is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. Update to Part I, Item 1 – Business of the Annual Report This Current Report on Form 8-K updates Part I, Item 1 – Business of the Annual Report on Form 10-K for the year ended December 31, 2025 (the “Annual Report”) of the Company to reflect the merger between the Company and Yarrow Bioscience Operating… the 8-K · retrieved 2026-11-21 00:44 UTC - 2026-08-13 8-K Item 2.02
Results of Operations and Financial Condition. This Amendment No. 1 includes (i) the financial statements of Pre-Merger Yarrow as of and for the three and six months ended June 30, 2026, (ii) the financial statements of Pre-Merger Yarrow as of December 31, 2025 and October 3, 2025, and for the period from October 3, 2025 (inception) to December 31, 2025, which have been recast to give retroactive effect to the Exchange Ratio, (iii) Pre-Merger Yarrow’s Management’s Discussion and Analysis of Financial Condition and Results of Operations as of and for the three and six months ended June 30, 2026, and (iv) the unaudited pro forma condensed combined balance sheet of the Company and Pre-Merger… the 8-K · retrieved 2026-11-21 00:44 UTC - 2026-08-13 8-K Item 7.01
Regulation FD Disclosure. On August 13, 2026, the Company made available an updated corporate presentation on the Company’s website. A copy of the corporate presentation is furnished as Exhibit 99.8 to this Amendment No. 1 and is incorporated herein by reference. This Item 7.01 and Exhibit 99.8 to this Amendment No. 1 are being furnished to the SEC and shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act, regardless of any general incorporation language in such filing. the 8-K · retrieved 2026-11-21 00:44 UTC
Each excerpt is the first part of the item's own text, copied as filed and cut at a word; the filing has the rest.
POSSIBLE MATCHES · LICENCES, PERMITS, CITY AND STATE RECORDS13. Permits and local records
2 state and city records carry this company's exact name, from 2 sources. Possible matches only.
Connecticut business registrations (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchYARROW BIOSCIENCE, INC. · exact legal name · sx:ctsos:3366353 Compare
ClinicalTrials.gov (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchYarrow Bioscience, Inc. · exact legal name · sx:ctgov:hb20ccba8f6343ba5 Compare
WHAT THIS PAGE READ
Sources
JSON · MCP · API
API and agents
The same profile as JSON: GET /company/1566044.json. The MCP server and the records API return the same data: GET /v1/record/sx:sec:0001566044. Every source URL used is listed in the file.
Get the evidence file, alerts and the API with a free key. Everything on this page stays free to read.